
Thermo Fisher Scientific Syncytin 2 Polyclonal Antibody, Biotin
인간 Syncytin-2 단백질(아미노산 80–130 영역)에서 유래한 합성 펩타이드로 제작된 Rabbit Polyclonal Antibody. Biotin 결합형으로 WB, ELISA, IP 등 다양한 응용에 적합. 고순도 친화 크로마토그래피 정제, 안정적 액상 형태로 연구용에 최적화.
- 카탈로그번호
- SYCY2-212BIOTIN
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific Syncytin 2 Polyclonal Antibody, Biotin
Applications
| Application | Tested Dilution |
|---|---|
| Western Blot (WB) | 1:500–1:1,000 |
| ELISA | 1:10,000 |
| Immunoprecipitation (IP) | 1:50–1:250 |
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | Synthetic peptide within amino acid region 80–130 on human Syncytin-2 protein |
| Conjugate | Biotin |
| Form | Liquid |
| Concentration | 0.5–1.5 mg/mL |
| Purification | Affinity chromatography |
| Storage Buffer | Proprietary buffer, pH 7.4–7.8, with 30% glycerol, 0.5% BSA |
| Contains | 0.02% sodium azide |
| Storage Conditions | −20°C |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
Target Information
Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost, or modified their original function during evolution. This endogenous envelope protein has retained its original fusogenic properties. HERV-FRD can make pseudotypes with MLV, HIV-1, or SIV-1 virions and confer infectivity.
Human endogenous retroviruses (HERVs) make up approximately 8% of the human genome. Although most HERVs are nonfunctional, the HERV-W (ERVWE1; MIM 604659) and HERV-FRD envelope (env) proteins can induce cell-cell fusion when expressed in cells possessing appropriate receptors (Blaise et al., 2003 [PubMed 14557543]). [supplied by OMIM].
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
